Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
August 13, 2026
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today. During this call, you'll be hearing from Howard Robin, who serves as our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Linda Rubinstein, our Chief Financial Officer. Dr. Mary Tagliaferri, our Chief Medical Officer, will also be around for the Q&A. Prior to getting started, I want to remind everyone that forward-looking statements about our business will be made, including ones concerning the therapeutic and commercial potential along with development plans for rezpegaldesleukin, the timing and expectations for clinical trials, clinical data presentations and regulatory submissions, regulatory interactions, our expected cash runway, and other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of which fall outside our control. To learn about these risks and uncertainties, please look at our filings with the SEC, including our most recent Form 10-K and subsequent filings. We take on no obligation to update these forward-looking statements, except as required by law. A live webcast and replay of this call can be accessed on the Investor Relations section of our website at nektar.com. With that, I'll turn the call over to Howard.
Howard Robin
executiveThanks, Vivian. And thanks to all of you for being with us on this call this afternoon. Back in July, we hit another significant milestone here at Nektar when we kicked off the global ZENITH AD program — that's our Phase III program in atopic dermatitis for rezpegaldesleukin, which we also call REZPEG, in patients with moderate to severe disease. We're thrilled to be moving this highly promising novel medicine toward registration in what is the first of several possible indications. After our end of Phase II meeting with the FDA, we locked in the design of a single registrational Phase III trial for REZPEG in alopecia areata, and we intend to launch that study in early 2027. These registrational designs for REZPEG are built on the favorable clinical data we produced during the first half of this year in atopic dermatitis and alopecia areata patients, and they also incorporate feedback from the regulatory meetings we've completed. JZ will go into more detail on these designs later in the call. And importantly, now that the first Phase III studies in atopic dermatitis are up and running, we anticipate top line data from them in mid-2028, and assuming those are positive, we expect to file a BLA in 2029. As a novel T-reg agonist mechanism, REZPEG operates in a fundamentally different way, working upstream of multiple inflammatory pathways to bring back immune balance. Along those lines, we keep assessing new indications to broaden REZPEG's development going forward. Through TrialNet, we're looking at its potential in type 1 diabetes in an ongoing Phase II study. We also think there are additional autoimmune conditions in which a T-reg mechanism might help patients, so we see REZPEG as a potential pipeline in a product. Importantly, the market opportunity and patient need in each of our 2 lead indications are substantial. Over 15 million people in the United States have moderate to severe atopic dermatitis, and right now fewer than 10% receive treatment with a systemic therapy. We believe this market will expand as novel mechanisms of action come in, just as happened in the psoriasis market, and that REZPEG is highly differentiated from the other novel MOAs that are approved or in development; we know that about half of patients on currently available IL-13-based agents, including Dupixent, either don't respond to therapy or lose their response over time. That leaves a large unmet need for a new therapeutic option. We believe REZPEG could reshape the treatment paradigm in this indication by delivering a differentiated efficacy and safety profile, along with a long-term, highly attractive monthly or quarterly maintenance dosing regimen. We recently finished extensive market research, which included our 52-week maintenance data for REZPEG. The research reinforces our commercial thesis in atopic dermatitis. We interviewed and surveyed 151 high-volume prescribers and key opinion leaders in the United States and Europe. One theme that came up repeatedly in the research was physician enthusiasm for a novel mechanism of action as compared to overlapping mechanisms of action in the IL-13 class. The REZOLVE-AD data was viewed highly positively, including EASI-75 and Itch NRS responses. During the quarter, the maintenance dosing given every three months drew attention as something distinctive and beneficial, and the EASI-100 response rates were highlighted the same way. Another point raised as a major differentiator was the information from patients with comorbid asthma, since doctors treat individuals who have various other autoimmune and allergic conditions alongside their primary diagnosis, and those patients might respond well to a T-reg therapeutic strategy. Of particular note, the safety profile stood out as a crucial differentiator, given that within our Phase IIb REZOLVE-AD trial, the REZPEG arms showed no elevated infection risk and no cases of conjunctivitis. What's more, of the 151 physicians surveyed, 150 reported that injection site reactions did not deter them from prescribing or create an obstacle for patients, and in fact they favored an ISR that resolves on its own and lasts only briefly rather than having to manage conjunctivitis that persists longer. Physicians clearly indicated they would embrace a new immune modulating mechanism such as REZPEG within the treatment landscape, and that REZPEG would probably be given to patients across first-, second-, and third-line groups. This research backs up our choice to seek a label through our registrational program in atopic dermatitis that includes both patients who have never been treated and those with prior treatment experience. Now shifting to the opportunity in alopecia areata. Roughly 6.7 million individuals across the United States live with this disease, and the vast majority receive no treatment at present. JAK inhibitors come with well-documented safety concerns, and as the sole approved drug class for severe patients, those concerns have restricted how much they are used. Even so, the market for treatments currently approved for alopecia areata is expected to reach $5 billion by 2033; yet over 50% of dermatologists feel uneasy about prescribing such agents because of their box warnings and the continuous monitoring requirements. Our REZPEG market research involving alopecia areata physicians confirms this reluctance to prescribe JAK inhibitors. Beyond the safety profile REZPEG has demonstrated so far and its innovative MOA, the physicians and patients in our research pointed to REZPEG's dosing twice each month for alopecia areata patients as being more appealing than taking an oral pill once daily. Physicians further observed that ensuring patients stick with treatment is far more achievable when using an injectable regimen taken twice monthly. This research reinforces our confidence that REZPEG could emerge as a preferred first-line option for individuals suffering from severe to very severe alopecia areata. Before handing things over to JZ, I want to mention that we closed the quarter from a position of financial strength, holding more than $1 billion in cash and investments, with our cash runway stretching into the third quarter of 2028, beyond when we expect the initial Phase III atopic dermatitis data readouts in mid-2028. Everyone on our team remains sharply focused on executing our Phase III programs successfully and moving REZPEG toward BLA submission as rapidly as we can. With that, I'll pass the call to JZ.
Jonathan Zalevsky
executiveHoward, thanks, and good afternoon to all of you. All the knowledge we've gained regarding REZPEG from clinical program data so far indicates a clinical profile that is consistent and, in our view, differentiated: meaningful efficacy, a favorable safety profile featuring dosing that is as infrequent as once every three months, and responses that keep getting deeper as time passes. As Howard said, in the diseases we're going after, REZPEG acts upstream of the agents approved today; it stimulates regulatory T cells and comes closest to natural causal biology in order to restore the immune balance that gets disrupted in autoimmune and inflammatory disease, instead of blocking one target, or even several targets, downstream. REZPEG is able to correct Th1, Th2, Th17, along with various other inflammatory dysfunctions upstream that can push disease pathology in atopic dermatitis, alopecia areata, and additional autoimmune conditions. Because regulatory T cells tackle the immune imbalance that sits beneath inflammatory and autoimmune disease, what we've seen is REZPEG produce durability that holds up very well over time. That idea served as our core hypothesis when we created REZPEG, and the results we shared from the monthly and quarterly dosing schedules in our Phase IIb program confirm it. In our initial Phase I trial, following a 12-week treatment cycle, responses clinically were durable for about 9 months after patients came off treatment, something we've previously published. Howard mentioned ZENITH-AD, and that trial—our atopic dermatitis Phase III effort worldwide—has officially launched. Two initial studies kicked off, enrolling only those who hadn't previously received biologics or JAK inhibitors, with patient randomization starting in July. By the close of September, a third study is scheduled to launch, this one involving individuals with prior treatment experience. For clarity, each of those two key biologic-naive trials aims to recruit 510 participants, adolescents and adults, all 12 or older, assigned in a 2:1 ratio to receive either REZPEG dosed at 24 micrograms per kilogram once every fortnight or a placebo. The design starts with a 24-week induction phase, then moves into a 28-week maintenance phase extending to week 52, where dosing will be assessed both monthly and quarterly. There's a third Phase III trial, and it enrolls patients who've already been treated before. Its design mirrors the other one, and the expectation is that it will back up second-line use and beyond in the label. When you look at all these studies together, the goal is to make possible a label for this population that includes both people who haven't received prior therapy and those who have, covering first line, second line, and later lines. The trials are built to enable registration both in the U.S. and around the world, using an IGA-based primary endpoint for the U.S. For major markets outside the U.S., the co-primary endpoints are EASI-75 and IGA, plus secondary endpoints with multiplicity protection covering key patient-reported outcomes — Itch numerical rating scale, or NRS, skin pain NRS, and the Atopic Dermatitis Sleep Scale, or ADSS. It's well known that a lot of atopic dermatitis sufferers deal with additional health issues too, such as asthma and allergic rhinitis. Because REZPEG relies on a T-reg-based mechanism, it was built to act upstream of targeted therapies — this gives REZPEG a distinctive ability to tackle several autoimmune and inflammatory conditions simultaneously. With that goal in mind, we're also adding a number of secondary endpoints that carry multiplicity protection, letting us explore this potential advantage. ACQ-5, a patient-reported gauge of asthma symptom improvement, is the first of these. Roughly 25% of individuals suffering from moderate to severe atopic dermatitis likewise contend with asthma; and within our Phase IIb trial, REZPEG achieved statistically significant gains on ACQ-5 compared with placebo, including among those whose asthma was uncontrolled at baseline. Another endpoint we have added is the Sino-Nasal Outcome Test 22, known by the acronym SNOT-22, a validated patient-reported gauge of Sino-Nasal symptoms. Rhinitis is a type 2 inflammatory comorbidity observed in atopic dermatitis patients. And as many as 30% of people with atopic dermatitis also carry a comorbidity of allergic rhinitis. For this endpoint in our Phase IIb study, we assessed SNOT-22 among patients with self-reported symptoms, extending also to those who self-reported asthma alongside rhinitis. SNOT-22 is being introduced as a secondary endpoint across our Phase III trials, and we're excited to share that we plan to showcase data on SNOT-22 from REZOLVE-AD at a medical meeting in the near future. The design of our Phase III program is built on the strong Phase IIb findings from REZOLVE-AD. During that study, skin clearance and itch relief arrived quickly after treatment began, and rather than leveling off, those improvements continued to deepen as time went on. Using less frequent maintenance dosing given monthly and quarterly, we saw high rates of complete skin clearance, including increases in EASI-100 rates of up to five times over the 36-week maintenance treatment period — a degree of response that is rarely achieved. Howard already covered this, but to recap: we expect to see the first set of results from the Phase III program around the middle of 2028, and assuming those come back positive, we plan to file a BLA during 2029. Now turning to alopecia areata — we just held our end of Phase II meeting with the FDA not long ago, and we came away with agreement on conducting one registrational Phase III trial, which will go by the name ZENITH-AA. For that pivotal trial, we've locked in a plan to randomize 850 patients, both adolescents and adults, ages 12 and up, who will get either REZPEG dosed at 24 micrograms per kilogram once every two weeks or a placebo, and dosing will run for a full 52 weeks. Enrollment will target individuals whose current alopecia areata episode has lasted as long as 8 years. Every JAK inhibitor Phase III trial used this as its inclusion criteria, and our Phase IIb randomized placebo-controlled study did too. Enrollment will include patients who haven't had systemic treatment before, whether biologics or JAK inhibitors, along with those who received a systemic agent previously, as long as they completed a lengthy washout period. At week 52, the primary endpoint is a SALT score at or below 20, meaning scalp hair coverage of at least 80%. For patients starting with severe to very severe alopecia areata, this is the recognized registrational endpoint. The key secondary endpoints encompass SALT scores at or below 10 and at or below 30, as well as reductions in SALT of 50%, 75%, and 90% relative to baseline, which reflect progressively greater amounts of hair regrowth. As you may remember, in our Phase IIb trial we saw improvement with REZPEG treatment on each of those endpoints. Participants in the trial will also have the chance to continue into an extended, long-term phase. That will let us characterize the durability of response during treatment as well as safety over the long term. We intend to kick off the Phase III alopecia areata trial at the start of 2027, and we expect to see data in the latter half of 2029. If those results turn out favorable, then once we've made our planned filing in atopic dermatitis, our next step would likely be to seek approval in alopecia areata as a second indication. Regarding the 24-week period without treatment in the Phase IIb REZOLVE-AA trial for alopecia areata, we're looking to have those results during this year's fourth quarter. What we aim to accomplish by measuring patients during the off-treatment period is to establish a maintenance dosing regimen past 52 weeks, either continuing twice-monthly dosing or providing an added once-a-month option. As you're aware, we already offer a favorable dosing schedule of twice monthly relative to a daily JAK inhibitor.
Jonathan Zalevsky
executiveLike Howard mentioned before, what we've seen in our market research confirms that patients along with physicians favor an injectable given less often rather than something taken orally each day. If you combine that advantage in dosing with the safety data we've seen so far, our view is that REZPEG could emerge as a significant first-line option for this indication. On top of that, abstracts from our two lead programs — atopic dermatitis and alopecia areata — have been cleared for oral presentations at the European Academy of Dermatology and Venereology, EADV, congress happening in Vienna this October. Those talks will highlight the REZOLVE-AD maintenance findings, covering patients who hold onto their response as well as those whose responses are new and deepening as time goes on, complete clearance included, plus the week 52 data from REZOLVE-AA. We feel thankful to have the chance to share this data at such a key meeting. Outside those 2 lead indications, the Phase II trial of REZPEG in new onset type 1 diabetes, which TrialNet sponsors and funds, is still underway. Just to remind everyone, TrialNet is the same consortium behind the foundational work on teplizumab, the sole approved therapy in this setting, and they carry both expertise and a strong dedication to finding improved options for people living with this disease. We're eager to see results from the first cohort in this type 1 diabetes study during 2027. While the program advances, we keep assessing further possibilities for REZPEG across other potential indications. And as I noted before, REZPEG works in a fundamentally different way than treatments that block just one downstream inflammatory mediator. REZPEG operates upstream, expanding regulatory T cells and boosting their suppressive capability, which restores immune tolerance and brings back regulatory control over pathogenic immune responses. Our goal is to launch a clinical study before the year ends, which would let us assess REZPEG's activity in a new indication. Now to our earlier-stage pipeline programs. Development of our TNFR2 programs is ongoing. NKTR-0165, our bivalent TNFR2 agonist antibody, is a molecule with extremely high specificity for TNFR2 signaling on T-regs, enhancing their capacity to regulate the immune system. We see potential for this mechanism across a variety of indications, such as MS, ulcerative colitis and vitiligo. Since NKTR-0165 showed strong monomeric activity, we recognized that the TNFR2 molecule could be built into the design of bispecific and trispecific constructs alongside validated targets. So we're building a pipeline of bispecific molecules containing TNFR2 that combine TNFR2 agonism with other antibody targets. The first such program, NKTR-0166, is a bispecific molecule pairing a TNFR2 agonist epitope with an antagonist epitope already validated in rheumatology. This dual mechanism means NKTR-0166 may be able to modify disease pathogenesis across numerous autoimmune settings. Research on both TNFR2 programs continues, and we'll share more as they move forward. With that, I'll hand the call over to Linda for our financial results. Linda?
Linda Rubinstein
executiveThanks, JZ, and good afternoon to all of you. During this call, I'll walk through the financial results we posted for the second quarter of 2026, along with the guidance we're providing for 2026. As of the close of the second quarter of 2026, we held $1.02 billion in cash and investments, and our balance sheet carries no debt. During April, we wrapped up an underwritten public offering that brought in net proceeds of roughly $350 million. Our cash guidance for the close of 2026 is going up, and our current expectation is to finish 2026 with somewhere around $815 million to $840 million in cash and investments. Now moving to the income statement. Noncash royalty revenue came in at $10.1 million for the second quarter of 2026. We still expect total revenue for the full year 2026 to land at $40 million to $45 million. R&D expenses for the second quarter of 2026 came to $39.1 million, and our updated outlook for full year R&D expense is a range of $210 million to $230 million, which includes roughly $5 million to $10 million in noncash depreciation and stock-based compensation expense. Keep in mind that we anticipate R&D expense rising quarter over quarter during 2026 as our Phase III clinical studies and the CMC activities supporting them move forward. G&A expenses totaled $12.8 million in the second quarter. For the full year 2026, we still anticipate G&A expenses of between $60 million and $65 million, including approximately $5 million in noncash depreciation and stock-based compensation expense. Noncash interest expense for the second quarter was $7.2 million, and for 2026 we expect noncash interest expense of approximately $30 million to $35 million in total. Our net loss for the second quarter reached $40.6 million, or $1.23 basic and diluted net loss per share. And as I mentioned before, we now anticipate closing out 2026 with between $815 million and $840 million in cash and investments. With a strong financial position, we're able to keep investing in our REZPEG atopic dermatitis and alopecia areata programs, and also keep advancing our TNFR2 agonist antibody program, which comprises NKTR-0165 and NKTR-0166. At this point, I'll hand things over to the operator for Q&A.
Yasmeen Rahimi
analystCongratulations on securing alignment for the ZENITH-AA study and getting it underway. So, congrats, and these are excellent updates. You always do a fantastic job of helping us consider what the next catalyst will be — thinking through timing, what kind of data we'll receive, and what to expect. I'd love to do that before the next key data readout, which is the withdrawal data set to arrive in Q4. Could you perhaps share what you're expecting regarding the cohort's size? What do you anticipate seeing there, and would any of that off-treatment AA data shape, in any way, how data collection proceeds in your Phase III trial?
Howard Robin
executiveYes. Thank you. That's an excellent question. I'll let Mary address it.
Mary Tagliaferri
executiveOkay, Yasmeen — I really appreciate you noting that our Phase III atopic dermatitis program has gotten underway. That's something we're quite thrilled about too. So, as you're aware, within REZOLVE-AA there's a 24-week period after treatment where we follow up with patients. That portion of the study is still running. Data from it will come in the fourth quarter. Altogether, 92 patients were enrolled in the trial, and out of those 92, a group of 31 moved into the 16-week extension. Everyone who entered the study is tracked through that 24-week off-treatment window. Now regarding Phase III, what matters most to us is that once 52 weeks of therapy have been completed in the registrational alopecia areata Phase III study, we'll keep monitoring those patients within a long-term extension study. Those findings should genuinely help guide whether dosing ought to remain every 2 weeks or whether we can stretch that interval during maintenance to something longer, like once a month. So we're eager to examine that information, since it would give us greater clarity about treatment past 52 weeks in our Phase III program. In the same vein, during the first quarter of next year, 52-week off-treatment results will be available from our atopic dermatitis Phase IIb study. There too, we're essentially trying to determine what dosing should look like following 52 weeks of treatment. And whether — or rather, whether some patients show durability of responses extending past, let's say, a dosing interval assessed in the Phase IIb, such as every 2 months and every 3 months. Naturally, in our Phase IIb we observed that patients had strong durability, and a lot of them saw their response deepen. What we now want to examine through this 52-week off-treatment period is how those responses hold up and how durable they remain, to determine whether extending the dosing interval past quarterly is workable.
Samantha Semenkow
analystThanks as well for every one of the specifics from that new market research you presented on atopic derm. I'd like to know whether you could say a little more about the way physicians are approaching the idea of prescribing REZPEG as a first-line option. Are there particular patient populations or traits that doctors are pointing to as the ones that fit REZPEG best? Also, did the market research you ran offer any signal about how the split would look between those who'd be candidates, let's say, for first line as opposed to second line or beyond?
Howard Robin
executiveYes, that's a really good question. See, the market research we ran was broad in scope, and our goal was to figure out how to position our drug, since at a certain point it's an entirely novel mechanism, and everyone assumes there has to be — will have to be — a step-through via IL-13 before you can ultimately reach something along the lines of a T-reg mechanism. And what we find is that this isn't true. I believe that, on the whole, as I mentioned before, roughly just 10% of the atopic dermatitis population is receiving treatment with systemic therapies. That means the upside market potential is huge. And even among the patients who are on IL-13s, which are more or less the gold standard at present, I'd say around half of them either don't respond or fail after about a year. So there's a great deal of opportunity for REZPEG as a first-line indication. Obviously, as a second-line indication, it matches that definition perfectly, because we know how many patients fail IL-13; and given a quarterly maintenance dosing regimen, it becomes a very easy drug for those patients to take. Still, I do believe we'll capture a meaningful share of the first-line market too, once patients gain experience. Keep in mind, it doesn't lead to any infection. It doesn't lead to conjunctivitis and those problems, and those side effects could be significantly more serious than mild to moderate self-resolving ISRs. So on balance, we're quite pleased about securing our first-line market share.
Jay Olson
analystSo when we consider possibly shifting into the first-line setting at some point.
Howard Robin
executiveApologies — I could hardly catch what you asked. Would you mind repeating it, but more loudly?
Cha Cha Yang
analystThis is Cha Cha calling in for Roger. Thanks a lot for the updates — as usual, they're very informative and very colorful. I wanted to ask whether you might share some thoughts about the pretrial that took place last week. Is there any color you can provide regarding how that turned out? And after that, what effect do you anticipate those results will have on the September trial that's coming up?
Howard Robin
executiveYes. Look, that's always a good question; but naturally, it's — you really can't — we really aren't able to say anything about litigation that's still ongoing. What I can say is that the trial is set — a jury trial is set to take place in federal court in San Francisco on September 8; and we feel we hold a very strong position; and regrettably that's everything I'm able to share with you right now. So I would love to tell you more, but commenting on active litigation is difficult.
Arthur He
analystCongratulations on the advancement. And Mary, nice work securing the single trial approval for the AA study. On that note, I'm curious — regarding the off-drug data coming in Q4, for the patients who only made it through the 36 weeks, will we also be examining data from that subset?
Mary Tagliaferri
executiveArthur, yes, we'll be evaluating both those patients and the ones who finished the full 52 weeks of treatment. Clearly, the group I believe will prove most useful and informative for our decision-making is that group. There were 31 of them who entered the long-term extension — who entered the 16-week extension. That said, we will be reviewing all 92 patients randomized into the study and giving an update on the complete set of findings.
Arthur He
analystAll right, just a quick follow-up question. When you spoke with the FDA, did they impose any kind of requirement regarding a medium or minimum duration for the current episode in alopecia patients?
Mary Tagliaferri
executiveYes. I appreciate you bringing that up. We're going to adhere to the same standard that applies to JAK inhibitors. And our trial design did allow for patients whose current episode has lasted as long as 8 years. We're aware that certain others have examined a more enriched patient population with a current episode lasting no more than 4 years; yet in our view that doesn't represent the real population of alopecia areata patients, and we're aiming for a very broad label. So we designed a study that will enroll both patients who are JAK inhibitor naive and those who are JAK inhibitor experienced; we'll include adolescent patients along with adult patients, and we'll be evaluating patients whose current episode duration is less than 4 years and those at 4 to 8 years. In our view, securing the broadest label offers the greatest commercial potential while also serving the widest share of patients, and certainly a study that aligns with the earlier JAK inhibitor studies.
Mayank Mamtani
analystI really like how thorough this has been. I've got a question with two parts; regarding EADV, what additional data can we look forward to seeing? Also, since it's October 1, which falls in the fourth quarter, is there any possibility that off-treatment REZOLVE-AA results might be shared too? Another thing—I'd love some insight into how enrollment enthusiasm is going for your global alopecia Phase III trial; then, about the maintenance atopic derm results, based only on your Phase Ib, where EASI-75 was sustained out to 9 months, could you point out how this off-treatment situation differs from what your Phase Ib showed? And might we also anticipate that certain EASI-100 responders maintain that off-treatment remission?
Mary Tagliaferri
executiveGreat. Mayank, thank you for those questions. Of course, like JZ said, having 2 oral presentations accepted at EADV makes us very happy. To me, that truly underscores the potential of our novel mechanism of action, along with the robustness of the clinical data we've generated. When the abstracts were submitted, naturally, the 24-week follow-up data weren't available to us. So obviously, that portion of our study isn't reflected in our abstract. That study remains ongoing and blinded. That said, it's possible we might be able to add the 24-week data, as you pointed out—that could prove quite valuable and generate considerable interest. No decision on that can be made right now. Should the data read out in time and we're prepared, we would be delighted to add those results to our oral presentation by Dr. David Rosmarin at EADV. That said, we can't commit to that at this moment, since the trial continues and we haven't locked that section of the database yet. Still, I appreciate you raising it. It's a possibility, though once more, it isn't in our abstract; as for your second question regarding the maintenance data and the 52-week off-treatment results from the Phase IIb atopic dermatitis trial, you're right—we previously presented off-treatment findings from our Phase Ib covering 9 months. What's different now is that we'll have 3 more months of follow-up after patients stop the drug. We believe examining that durability of responses is incredibly important for us; once again, we'll be able to assess EASI-75 and, as you noted, EASI-100 and EASI-90. We consistently observed that patients kept improving while on REZPEG treatment, and we saw that response deepen. Now our focus shifts to these patients while off treatment, and we'll be able to assess the 9-month point just as we did in Phase Ib, plus 52 weeks off treatment. Figuring out the best dosing schedule is going to be really important; once patients reach 52 weeks on therapy, is it possible for maintenance doses to be given less often — and for certain individuals, the gap might stretch beyond 3 months. So we can't wait to see those results and take a very careful look at how long those responses hold up. Thanks for raising those 2 questions.
Julian Harrison
analystCongratulations on everything that's happened lately. To start, I'd like to know whether your thinking has changed regarding how REZPEG stacks up competitively in alopecia areata, given a recent data set that came out last month from a different non-JAK treatment candidate being developed in the wider field. Then, zooming out, with REZPEG's pipeline and product potential in mind, I'm curious whether you've given any thought to backing signal-seeking work conducted through an IIT. I'm certain you've received some investigator requests. Would you be open to that? Or do you feel upcoming trials are better kept entirely under Nektar's control?
Howard Robin
executiveYes, those are 2 excellent questions. So to begin with, on the competitive picture in alopecia areata — look, the study whose data was just released, and I'll have Mary add a bit more here, is very hard to interpret. On top of that, it was a single-arm study. So it wasn't blinded. It's somewhat hard to interpret. And honestly, the patient population it enrolled was far less severe, or far earlier in the course of disease, than the group we intend to study. I believe Mary spoke about the gap between 4 years and 8 years; I'll let her address that shortly. As for your second question, about exploring other indications, yes, we're currently working out which indications we'd like to run pilot studies in so we can obtain proof-of-concept data. I think — look, we had a great deal of success in the lupus study when we reviewed the data using weight-based dosing instead of fixed-based dosing. And I think there's potential in cutaneous lupus too; plus a number of other indications, much like what we're pursuing in type 1 diabetes, that might justify a — whether that's an investigator-sponsored trial, where you perhaps give up a bit of control, or our own pilot studies. I really do believe that to bolster the value of a T-reg mechanism, there are other indications we'll be examining. I'll hand it back to Mary for more insight on your first question.
Mary Tagliaferri
executiveAbsolutely. Julians, Howard brought this up during our prepared remarks; from our perspective, the alopecia areata market is extremely big. And without a doubt, JAK inhibitors leave these patients with unmet needs. So, as experienced biotech leaders, doctors, and researchers, we’re passionate about innovation, and we enjoy witnessing innovation in an area with enormous room to grow; that said, as Howard pointed out, the Q32 data are genuinely hard to make sense of. It was a tiny, just 33 patients, open-label trial without any placebo; and as we’ve now said on two occasions, selecting a narrow patient group and limiting who qualifies truly biases outcomes toward whatever drug is under investigation. In contrast, our Phase IIb trial was randomized and placebo-controlled; we evaluated multiple doses. We permitted a wide patient population that aligned with JAK inhibitor trials. So there’s greater potential for generalizability; and we ran a very typical Phase IIb study that the FDA subsequently accepted as adequate to advance into a Phase III trial; so in the end, we continue to feel very positive about our efficacy and safety profile. And I’m aware that the broader dermatology community is eagerly anticipating the start of enrollment in our trial during Q1 of next year for these reasons. So thank you for the question.
Marc Frahm
analystCongratulations on the strides made toward launching that Phase III. Howard, perhaps you could expand a bit on the varying unmet needs within the AD space, especially when considering patients who've never received treatment compared with those who have? How do you anticipate that will shape the comparative speed of enrollment across these Phase III trials — the 2 distinct types, the differing patient numbers, and the varying degrees of unmet need?
Howard Robin
executiveYeah, that's a solid question. Given that OX40s aren't available, the possibilities for fresh mechanisms of action are definitely constrained. REZPEG stands out as clearly distinctive in that regard, so enrollment shouldn't pose a problem, in my view. In fact, I expect it to move along quite rapidly. I can't predict precisely how it will unfold. These studies have only just begun, yet I'm optimistic about a fairly quick pace, keeping in mind that with a novel mechanism, essentially nothing else exists right now. We'll find out what the STAT6 results show once that data arrives. Still, I don't believe that mechanism is as comprehensive as REZPEG. If you want, I can have JZ weigh in on that briefly. Broadly speaking, though, I think the size of this market escapes most people. Suppose by 2033 the market reaches roughly $35 billion — that reflects 10% of patients receiving treatment. Sure, other effective drugs exist. Apogee's product, for instance, is definitely a strong one. STAT6 may prove to be a highly significant mechanism. Even so, the reality is that this market is massive. When you possess a novel mechanism, you ought to capture a decent share of a market that, at 10% of patients treated, is already projected to hit $35 billion. I'll hand it to JZ to say a few words about why we regard REZPEG as possibly among the finest opportunities for addressing a condition such as AD.
Jonathan Zalevsky
executiveYeah. Marc, I appreciate that, Howard. So, to start, I believe this topic came up quickly earlier. One finding from our market research is that strong first-line penetration seemed likely for us. The reason is that essentially all the options physicians currently have, plus even what's in development — things such as STAT6 agents — are going after the very same pathway, correct? They sit in a strongly Th2-dominant inhibitory state. They might hit more than one node, yet the pathway they affect is still just one. And what our market research indicates is that physicians placed huge importance on a fresh MOA. A number of them said they'd turn to a new MOA first, so we believe that will do a lot to put REZPEG in a strong spot. As you've heard regarding how our Phase III study is designed, it isn't merely drawing on what we've learned — it's actually building further on the area where our Phase II data showed the most differentiation, and they're driving that even harder so REZPEG gets a substantial shot at a deeply differentiated label once this registrational program concludes.
Jessica Fye
analystCould you go into a bit more detail about what you expect for REZPEG's effect size in AD patients who've had biologics versus those who haven't? Also, when it comes to benchmarking the Phase III AD trial you're conducting in biologic-experienced patients, would Ebglyss be a solid comparison? If it wouldn't, then what ought we to consider?
Howard Robin
executiveAll right. Thank you for asking that. That's a really good question. Either JZ or Mary will address it with more specifics, but what I can say is that we examined quite carefully whether any biological or mechanistic rationale exists for a patient who doesn't respond to IL-13 to also fail on a totally different mechanism, and no such reason turned up; so I don't — my view is that we ought to succeed when treating patients with prior exposure. I'll hand it to JZ and Mary to say a bit more on that.
Mary Tagliaferri
executiveAbsolutely, I can kick things off, and then JZ can wrap up. Jessica, you're raising something really key here. Lebrikizumab underwent evaluation in the ADAPT trial, and those participants had received lebrikizumab following treatment with Dupixent, and efficacy didn't drop off at all. Among patients previously exposed to Dupi who then got lebrikizumab, 57% achieved EASI-75 by week 16. Then, looking at the lebri Phase III trials, ADvocate-1 along with ADvocate-2, EASI-75 at week 16 came in at 52% and 59% within that naive group. So we — plus ADAPT also enrolled patients who'd shown an insufficient response to dupi as well; so with that precedent, those trial results, and the REZPEG mechanism of action, which boosts the regulatory networks instead of merely blocking one downstream inflammatory mediator, we anticipate efficacy among biologic and JAK inhibitor experienced patients will look very much like what we see in naive patients. And I'll hand it to JZ to go deeper on the mechanism of action if you'd like, JZ.
Jonathan Zalevsky
executiveNo, thank you. And I believe you hit on quite a few of the essential items that our mechanism involving T-reg induction, if anything, is intended to genuinely assist patients for whom blocking IL-13 or IL-4 and 13 no longer does enough, correct, to keep their disease under control. That's among the best aspects, right, of the T-reg strategy — it works upstream of every one of those factors. And we're eager to keep expanding on that. You brought up a really significant point, which is that although the ADAPT study is valuable, as Mary described, it is open-label and single-arm. Consequently, a genuine benchmark hasn't actually been published, for instance, regarding placebo among this patient population. So each of these items will be part of some potential data to be reported should Sanofi report the findings of their amlitelimab study in this patient population. That one was built as a randomized controlled trial. It will generate a single important piece of placebo information. Yet on the whole, we're incredibly thrilled to include this third study within our registrational program. We anticipate REZPEG has an extremely strong chance of being efficacious in this patient population for every reason we've laid out; and having a study of that kind under REZPEG's belt as part of our BLA, it truly permits us to secure a far more differentiated label for REZPEG.
Andy Hsieh
analystSo Howard, you brought up that physician survey you conducted. Having you walk us through it is really useful. What I want to know is whether you asked the group about durability as a way to stand apart. Do these doctors have a particular window in mind, whether that's 3 months or 6 months? Then my second question relates to the type 1 diabetes study you're doing with TrialNet. From what it looks like, REZPEG gets administered for 6 months, yet the primary endpoint gets assessed at 12 months. Does that let us conclude there's some degree of off treatment effect we can extrapolate from that trial?
Howard Robin
executiveSure. Those are very good questions. I'll have Mary address the TrialNet type 1 diabetes study question. From our market research, I can tell you that time, duration or onset of action mattered, but long-term durability matters most. And that shows up when you look at our maintenance data — the drug — the results keep growing stronger and stronger, and my expectation is they'll keep going that way. Another thing that mattered a great deal to physicians, I think, was a manageable side effect profile. And like I said, ISRs didn't bother them in the least. They were much more — they were actually far more worried about infections and conjunctivitis than about ISRs. But on the whole, a durability of response that keeps improving mattered a lot to the physicians. Mary, would you like to take the type 1 diabetes trial question.
Jonathan Zalevsky
executiveAppreciate that, Howard. I'll go ahead and take care of it. So, sure, I'd like to give you some detail on the way that trial is put together. If you remember the teplizumab trials, the CD3 antibody — the mechanism there is that you get a really brief course of treatment, correct? Only a handful of cycles right at the start. Yet that turns out to be sufficient to shift the entire course of the illness. So TrialNet was quite enthusiastic that with REZPEG they were able to give doses for a longer stretch than had been the case with teplizumab. That got them excited; as a result, they went with a 6-month course. As for the mixed meal tolerance test C-peptide levels, those get measured across a year. Measurements happen while treatment is ongoing and also across the 6 months following it. Still, the overall theory and grasp of this disease, how it advances and the deterioration patients experience — it's widely accepted that a round of intervention will shift the entire slope of the illness and deliver the therapeutic benefit we're after. That's the reason the trial was set up in this manner. It sits very much in the — squarely within the sweet spot for how these type 1 diabetes studies get conducted.
Howard Robin
executiveWell, thanks to all of you for being with us today. It isn't every day that a business comes up with a fresh MOA that could really make a difference for patients who need help. I'd also like to express my appreciation to our staff for their hard work and dedication, as well as to our investors for sticking with us. So keep watching, and once again, many thanks. Good afternoon.
Operator
operatorThat brings us to the end of this conference call. We appreciate everyone for joining in. You can go ahead and disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.